Candel Therapeutics director granted 32,000 options
Candel Therapeutics director Paul B. Manning received a grant of stock options covering 32,000 shares of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Candel Therapeutics director Paul B. Manning received a grant of stock options covering 32,000 shares of common stock. The options have an exercise price of $9.08 per share and expire on June 23, 2036. Following this award, he holds 32,000 stock options directly.
The option is subject to time-based vesting. The underlying shares vest and become exercisable on the earlier of June 23, 2027 or the date of the next Annual Meeting of Stockholders, and vesting stops if he leaves the board unless the board determines otherwise.
Insider Trade Summary
Grant/Award: 32,000 shares
Grant/Award
1 txn
Insider
Manning Paul B
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 32,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 32,000 contracts (Direct)
Footnotes (1)
- F1. This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 23, 2027 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting.
Key Figures
Option grant size: 32,000 options
Exercise price: $9.08 per share
Underlying shares: 32,000 shares
+3 more
6 metrics
Option grant size
32,000 options
Director stock option award to Paul B. Manning
Exercise price
$9.08 per share
Strike price of granted stock options
Underlying shares
32,000 shares
Common stock underlying the option grant
Expiration date
June 23, 2036
Option term end date
Shares held after grant
32,000 derivative securities
Total stock options held following transaction
Latest vesting date
June 23, 2027
Latest date options vest, or earlier at next annual meeting
Key Terms
Stock Option (Right to Buy), time-based vesting, Annual Meeting of Stockholders, exercise price, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
time-based vesting financial
"This option is subject to time-based vesting."
Time-based vesting is a schedule that gives employees or contractors ownership of granted stock or options gradually as they remain with a company, like unlocking rewards in a loyalty program the longer you stick around. For investors, it matters because it affects future share supply, management incentives and staff retention — all of which can influence company performance and dilution of existing shareholders.
Annual Meeting of Stockholders financial
"the date of the next Annual Meeting of Stockholders of the Issuer"
exercise price financial
"conversion_or_exercise_price: 9.0800"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-06-23T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Candel Therapeutics (CADL) report in this Form 4 for Paul B. Manning?
Candel Therapeutics reported that director Paul B. Manning received a grant of stock options for 32,000 shares. These options give him the right to buy common stock at a fixed exercise price if the vesting conditions are satisfied.
How many Candel Therapeutics (CADL) options were granted to Paul B. Manning?
Paul B. Manning was granted stock options covering 32,000 shares of Candel Therapeutics common stock. The filing shows this entire amount as newly acquired options, with 32,000 derivative securities reported as held following the transaction.
What is the exercise price of Paul B. Manning’s CADL stock options?
The exercise price of Paul B. Manning’s Candel Therapeutics stock options is $9.08 per share. This means he can purchase common shares at $9.08 once the options vest and become exercisable under the stated vesting schedule.
When do Paul B. Manning’s Candel Therapeutics (CADL) options vest?
The options vest on the earlier of June 23, 2027 or the date of Candel Therapeutics’ next Annual Meeting of Stockholders. Vesting stops if he resigns or otherwise ceases to serve as a director, unless the board decides to continue vesting.
What is the expiration date of Paul B. Manning’s CADL stock options?
The stock options granted to Paul B. Manning expire on June 23, 2036. After that expiration date, any unexercised portion of the 32,000-share option grant can no longer be used to purchase Candel Therapeutics common stock.
Are Paul B. Manning’s Candel Therapeutics (CADL) options immediately exercisable?
The options are not immediately exercisable because they are subject to time-based vesting. They become exercisable when vesting occurs on the earlier of June 23, 2027 or the next Annual Meeting of Stockholders, subject to his continued service as a director.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates